Pasar al contenido principal

ACTIVACION ESPONTANEA DE LA VIA ALTERNATIVA DEL COMPLEMENTO Y SU RELEVANCIA EN LA ENFERMEDAD RENAL POR DEPOSITO DENSO

RTI2018-102242-B-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2018
Plan Estatal 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pseudomonas aeruginosa adaptation in cystic fibrosis patients increases C5a levels and promotes neutrophil recruitment

  • Mateu-Borrás, Margalida
  • González-Alsina, Álex
  • Doménech-Sánchez, Antonio
  • Querol-García, Javier
  • Fernández, Francisco J.
  • Vega, María Cristina
  • Albertí, Sebastián
10p.-5 fig.-1 tab., Cystic fibrosis (CF) disease is characterized by an intense airway inflammatory response mediated by neutrophils and chronic respiratory infections caused by P. aeruginosa. High levels of the complement component C5a, the strongest neutrophil chemoattractant molecule, are commonly found in the CF lung and have been associated with a worsening of the disease. In this study, we investigated how the isolates from CF patients modulate the levels of C5a and identified the bacterial factors involved. We demonstrated that most isolates from airway chronic infections induce the production and accumulation of C5a, an effect attributable to the loss of C5a cleavage by the exoproteases alkaline protease (AprA) and elastase B (LasB). Furthermore, we found that lack of the bacterial protease-dependent C5a degradation is due to mutations in the master regulator LasR. Thus, complementation of a non-C5a-cleaving CF isolate with a functional wild-type LasR restored its ability to express both proteases, cleave C5a and reduce neutrophil recruitment in vitro. These findings suggest that the non-cleaving C5a phenotype acquired by the LasR variants frequently isolated in CF patients may account for the strong neutrophilia and general neutrophil dysfunction predisposing toward increased inflammation and reduced bacterial clearance described in CF patients., This work was supported by the Spanish Ministry of Science and Innovation and European Regional Development Fund (FEDER) under Grant RTI2018-100701-B-100 to SA and RTI2018-102242-B-I00 to MCV, and by the Comunidad de Madrid under Grant S2017/BMD-3673 to MCV., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Generation of a soluble form of human endoglin fused to green fluorescent protein

  • Ruiz-Llorente, Lidia
  • Vega, María Cristina
  • Fernández, Francisco J.
  • Langa, Carmen
  • Morrell, Nicholas W.
  • Upton, Paul D.
  • Bernabéu, Carmelo
13 p.-5 fig., Endoglin (Eng, CD105) is a type I membrane glycoprotein that functions in endothelial cells as an auxiliary receptor for transforming growth factor β (TGF-β)/bone morphogenetic protein (BMP) family members and as an integrin ligand, modulating the vascular pathophysiology. Besides the membrane-bound endoglin, there is a soluble form of endoglin (sEng) that can be generated by the action of the matrix metalloproteinase (MMP)-14 or -12 on the juxtamembrane region of its ectodomain. High levels of sEng have been reported in patients with preeclampsia, hypercholesterolemia, atherosclerosis and cancer. In addition, sEng is a marker of cardiovascular damage in patients with hypertension and diabetes, plays a pathogenic role in preeclampsia, and inhibits angiogenesis and tumor proliferation, migration, and invasion in cancer. However, the mechanisms of action of sEng have not yet been elucidated, and new tools and experimental approaches are necessary to advance in this field. To this end, we aimed to obtain a fluorescent form of sEng as a new tool for biological imaging. Thus, we cloned the extracellular domain of endoglin in the pEGFP-N1 plasmid to generate a fusion protein with green fluorescent protein (GFP), giving rise to pEGFP-N1/Eng.EC. The recombinant fusion protein was characterized by transient and stable transfections in CHO-K1 cells using fluorescence microscopy, SDS-PAGE, immunodetection, and ELISA techniques. Upon transfection with pEGFP-N1/Eng.EC, fluorescence was readily detected in cells, indicating that the GFP contained in the recombinant protein was properly folded into the cytosol. Furthermore, as evidenced by Western blot analysis, the secreted fusion protein yielded the expected molecular mass and displayed a specific fluorescent signal. The fusion protein was also able to bind to BMP9 and BMP10 in vitro. Therefore, the construct described here could be used as a tool for functional in vitro studies of the extracellular domain of endoglin., This research was funded by grants from Ministerio de Ciencia, Innovación y Universidades of Spain (SAF2013-43421-R to C.B. and RTI2018-102242-B-I00 to M.C.V.), Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER; ISCIII-CB06/07/0038 to C.B. and contract CNV-234-PRF-360 to L.R.-L.) and Consejo Superior de Investigaciones Científicas (CSIC; 201920E022 to C.B.) and the British Heart Foundation (Programme Grant RG/19/3/34265 to P.D.U. and N.W.M.). CIBERER is an initiative of the Instituto de Salud Carlos III (ISCIII) of Spain supported by FEDER funds., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The crystal structure of iC3b-CR3 αI reveals a modular recognition of the main opsonin iC3b by the CR3 integrin receptor

  • Fernández, Francisco J.
  • Santos-López, Jorge
  • Martínez-Barricarte, Rubén
  • Querol-García, Javier
  • Martín Merinero, Héctor
  • Navas-Yuste, Sergio
  • Savko, Martin
  • Shepard, William E.
  • Rodríguez de Córdoba, Santiago
  • Vega, María Cristina
16 p.-9 fig., Complement activation on cell surfaces leads to the massive deposition of C3b, iC3b, and C3dg, the main complement opsonins. Recognition of iC3b by complement receptor type 3 (CR3) fosters pathogen opsonophagocytosis by macrophages and the stimulation of adaptive immunity by complement-opsonized antigens. Here, we present the crystallographic structure of the complex between human iC3b and the von Willebrand A inserted domain of the α chain of CR3 (αI). The crystal contains two composite interfaces for CR3 αI, encompassing distinct sets of contiguous macroglobulin (MG) domains on the C3c moiety, MG1-MG2 and MG6-MG7 domains. These composite binding sites define two iC3b-CR3 αI complexes characterized by specific rearrangements of the two semi-independent modules, C3c moiety and TED domain. Furthermore, we show the structure of iC3b in a physiologically-relevant extended conformation. Based on previously available data and novel insights reported herein, we propose an integrative model that reconciles conflicting facts about iC3b structure and function and explains the molecular basis for iC3b selective recognition by CR3 on opsonized surfaces., This work was funded by Spanish Ministerio de Ciencia, Innovación y Universidades-FEDER grant RTI2018-102242-B-I00 (to M.C.V.) and PID2019-104912RB-I00 (to S.R.C.), and Spanish Ministerio de Economía y Competitividad-FEDER grants SAF2015-72961-EXP (to M.C.V.) and SAF2015-66287-R (to S.R.C.). It was also funded by Grant S2017/BMD-3673 of the Regional Government of Madrid and the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) (SGL2103020) (to S.R.C. and M.C.V.), and the CSIC Special Intramural Grant PIE-201620E064 (to M.C.V.). It was additionally supported by the Network of Excellence Complement in Health and Disease (SAF2016-81876-REDT). SRC was also supported by the CIBER de Enfermedades Raras. JSL acknowledges the support of the PhD program in Molecular Biosciences of the Universidad Autónoma de Madrid (UAM) and the Ministry of Education, Culture and Sports of Spain (FPU Grant 17/06090). SNY acknowledges the support of the PhD program in Biochemistry, Molecular Biology and Biomedicine of the Universidad Complutense de Madrid (UCM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The hidden side of complement regulator C4BP: dissection and evaluation of its immunomodulatory activity

  • Serrano, Inmaculada
  • Luque, Ana
  • Mitjavila, F.
  • Blom, Anna M.
  • Rodríguez de Córdoba, Santiago
  • Vega, María Cristina
  • Torras, Joan
  • Aran, Josep M.
16 p.-9 fig., C4b-binding protein (C4BP) is a well-known regulator of the complement system that holds additional and important activities unrelated to complement inhibition. Recently, we have described a novel immunomodulatory activity in the minor C4BP(β-) isoform directly acting over inflammatory phagocytes. Here we show that incorporation of the β-chain to the C4BP α-chain oligomer interferes with this immunomodulatory activity of C4BP. Moreover, an oligomeric form including only the complement control protein 6 (CCP6) domain of the C4BP α-chain (PRP6-HO7) is sufficient to “reprogram” monocyte-derived DCs (Mo-DCs) from a pro-inflammatory and immunogenic phenotype to an anti-inflammatory and tolerogenic state. PRP6-HO7 lacks complement regulatory activity but retains full immunomodulatory activity over inflammatory Mo-DCs induced by TLRs, characterized by downregulation of relevant surface markers such as CD83, HLA-DR, co-stimulatory molecules such as CD86, CD80 and CD40, and pro-inflammatory cytokines such as IL-12 and TNF-α. Furthermore, PRP6-HO7-treated Mo-DCs shows increased endocytosis, significantly reduced CCR7 expression and CCL21-mediated chemotaxis, and prevents T cell alloproliferation. Finally, PRP6-HO7 shows also full immunomodulatory activity over Mo-DCs isolated from lupus nephritis patients with active disease, even without further pro-inflammatory stimulation. Therefore PRP6-HO7, retaining the immunomodulatory activity of C4BP(β-) and lacking its complement regulatory activity, might represent a promising and novel alternative to treat autoimmune diseases., We thank CERCA Programme/Generalitat de Catalunya for institutional support. This work was supported by the Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain) (grants FIS-ISCIII PI20/00464, PI16/00377 and DTS20/00016), and the “Departament de Recerca i Universitats de la Generalitat de Catalunya” (grants 2019PROD00081 and 2017SGR291), all co-funded by FEDER funds/European Regional Development Fund (ERDF)-a way to build Europe-. Dr. Vega is supported by the Spanish “Ministerio de Ciencia, Innovación y Universidades/FEDER” [RTI2018-102242-B-I00]. Dr. Rodriguez de Córdoba is supported by the Spanish “Ministerio de Economia y Competitividad/FEDER [SAF2015-66287-R]. Dr. Vega and Dr. Rodriguez de Córdoba are also funded by the Autonomous Region of Madrid [S2017/BMD-3673] and the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) [SGL2103020]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Soluble endoglin reduces thrombus formation and platelet aggregation via interaction with αIIbβ3 integrin

  • Rossi, Elisa
  • Pericacho, Miguel
  • Kauskot, Alexandre
  • Gamella-Pozuelo, Luis
  • Reboul, Etienne
  • Alexandre, Leuci
  • Egido‑Turrión, Cristina
  • El Hamaoui, Divina
  • Marchelli, Aurore
  • Fernández, Francisco J.
  • Margaill, Isabelle
  • Vega, María Cristina
  • Gaussem, Pascale
  • Pasquali, Samuela
  • Smadja, David M.
  • Bachelot-Loza, Christilla
  • Bernabéu, Carmelo
14 p.-6 fig., Background: The circulating form of human endoglin (sEng) is a cleavage product of membrane-bound endoglin present on endothelial cells. Because sEng encompasses an RGD motif involved in integrin binding, we hypothesized that sEng would be able to bind integrin αIIbβ3, thereby compromising platelet binding to fibrinogen and thrombus stability., Methods: In vitro human platelet aggregation, thrombus retraction, and secretion-competition assays were performed in the presence of sEng. Surface plasmon resonance (SPR) binding and computational (docking) analyses were carried out to evaluate protein-protein interactions. A transgenic mouse overexpressing human sEng (hsEng+) was used to measure bleeding/rebleeding, prothrombin time (PT), blood stream, and embolus formation after FeCl3-induced injury of the carotid artery., Results: Under flow conditions, supplementation of human whole blood with sEng led to a smaller thrombus size. sEng inhibited platelet aggregation and thrombus retraction, interfering with fibrinogen binding, but did not affect platelet activation. SPR binding studies demonstrated that the specific interaction between αIIbβ3 and sEng and molecular modeling showed a good fitting between αIIbβ3 and sEng structures involving the endoglin RGD motif, suggesting the possible formation of a highly stable αIIbβ3/sEng. hsEng+ mice showed increased bleeding time and number of rebleedings compared to wild-type mice. No differences in PT were denoted between genotypes. After FeCl3 injury, the number of released emboli in hsEng+ mice was higher and the occlusion was slower compared to controls., Conclusions: Our results demonstrate that sEng interferes with thrombus formation and stabilization, likely via its binding to platelet αIIbβ3, suggesting its involvement in primary hemostasis control., Promex Stiftung für die Forschung Foundation Consejo Superior de Investigaciones Científicas; Grant/Award Number: 201920E022 Spanish Ministry of Science, Innovation & Universities; Grant/Award Number: RTI2018-102242-B-I00 Comunidad de Madrid; Grant/Award Number: S2022/BMD-7278, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The structure of Leptospira interrogans GAPDH sheds light into an immunoevasion factor that can target the anaphylatoxin C5a of innate immunity

  • Navas-Yuste, Sergio
  • De la Paz-García, Karla
  • Querol-García, Javier
  • Gómez, Sara
  • Rodríguez de Córdoba, Santiago
  • Fernández, Francisco J.
  • Vega, María Cristina
15 p.-7 fig.-4 tab., Leptospirosis is a neglected worldwide zoonosis involving farm animals and domestic pets caused by the Gram-negative spirochete Leptospira interrogans.This bacterium deploys a variety of immune evasive mechanisms, some of them targeted at the complement system of the host’s innate immunity. In this work, we have solved the X-ray crystallographic structure of L. interrogans glyceraldehyde-3-phosphate dehydrogenase (GAPDH) to 2.37-Å resolution, a glycolytic enzyme that has been shown to exhibit moonlighting functions that potentiate infectivity and immune evasion in various pathogenic organisms.Besides, we have characterized the enzyme’s kinetic parameters toward the cognate substrates and have proven that the two natural products anacardic acid and curcumin are able to inhibit L. interrogans GAPDH at micromolar concentration through a noncompetitive inhibition modality. Furthermore, we have established that L. interrogans GAPDH can interact with the anaphylatoxin C5a of human innate immunity in vitro using bio-layer interferometry and a short-range cross-linking reagent that tethers free thiol groups in protein complexes. To shed light into the interaction between L. interrogans GAPDH and C5a, we have also carried out cross-link guided protein-protein docking. These results suggest that L. interrogans could be placed in the growing list of bacterial pathogens that exploit glycolytic enzymes as extracellular immune evasive factors. Analysis of the docking results indicates a low affinity interaction that is consistent with previous evidence, including known binding modes of other a-helical proteins with GAPDH. These findings allow us to propose L. interrogans GAPDH as a potential immune evasive factor targeting the complement system., This work was funded by Spanish Ministerio de Ciencia, Innovación y Universidades-FEDER grants RTI2018-102242-B-I00 (to MCV) and PID2019-104912RB-I00 (to SRdC); and the Spanish Ministerio de Ciencia e Innovación-Recovery, Transformation and Resilience Plan (PRTR) grant PDC2022-133713-I00. It was also funded by Grants S2017/BMD-3673 and S2022/BMD-7278 of the Regional Government of Madrid and the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) (SGL2103020) (to SRdC and MCV), and the CSIC Special Intramural Grant PIE-201620E064 (to MCV). It was additionally supported by the Research Network on Complement in Health and Disease (RED2022-134750-T). SRdC was also supported by the CIBER de Enfermedades Raras. KdlP was supported by an Industrial PhD grant (IND2018-010094) awarded by the Spanish Ministerio de Economía y Competitividad., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

C4BP(β-)-mediated immunomodulation attenuates inflammation in DSS-induced murine colitis and in myeloid cells from IBD patients

  • Serrano, Inmaculada
  • Luque, Ana
  • Ruiz-Cerulla, Alexandra
  • Navas, Sergio
  • Blom, Anna M.
  • Rodríguez de Córdoba, Santiago
  • Fernández, Francisco J.
  • Vega, María Cristina
  • Rodríguez-Moranta, Francisco
  • Guardiola, Jordi
  • Aran, Josep M.
16 p.-9 fig.-1 tab., The most recent and promising therapeutic strategies for inflammatory bowel disease (IBD) have engaged biologics targeting single effector components involved in major steps of the immune-inflammatory processes, such as tumor necrosis factor, interleukins or integrins. Nevertheless, these molecules have not yet met expectations regarding efficacy and safety, resulting in a significant percentage of refractory or relapsing patients. Thus, novel treatment options are urgently needed. The minor isoform of the complement inhibitor C4b-binding protein, C4BP(β-), has been shown to confer a robust anti-inflammatory and immunomodulatory phenotype over inflammatory myeloid cells. Here we show that C4BP(β-)-mediated immunomodulation can significantly attenuate the histopathological traits and preserve the intestinal epithelial integrity in dextran sulfate sodium (DSS)-induced murine colitis. C4BP(β-) downregulated inflammatory transcripts, notably those related to neutrophil activity, mitigated circulating inflammatory effector cytokines and chemokines such as CXCL13, key in generating ectopic lymphoid structures, and, overall, prevented inflammatory immune cell infiltration in the colon of colitic mice. PRP6-HO7, a recombinant curtailed analogue with only immunomodulatory activity, achieved a similar outcome as C4BP(β-), indicating that the therapeutic effect is not due to the complement inhibitory activity. Furthermore, both C4BP(β-) and PRP6-HO7 significantly reduced, with comparable efficacy, the intrinsic and TLR-induced inflammatory markers in myeloid cells from both ulcerative colitis and Crohn’s disease patients, regardless of their medication. Thus, the pleiotropic anti-inflammatory and immunomodulatory activity of PRP6-HO7, able to “reprogram” myeloid cells from the complex inflammatory bowel environment and to restore immune homeostasis, might constitute a promising therapeutic option for IBD., We thank CERCA Programme/Generalitat de Catalunya for institutional support. This work was supported by the Ministerio de Ciencia, Innovación y Universidades (Madrid, Spain) (grants FIS-ISCIII PI20/00464, PI16/00377 and DTS20/00016), and the “Departament de Recerca i Universitats de la Generalitat de Catalunya” (grants 2019PROD00081, 2021INNOV00020, and 2021SGR00521), all co-funded by FEDER funds/European Regional Development Fund (ERDF)-a way to build Europe-. Additionally, the project that gave rise to these results has received funding from the “La Caixa” Foundation and the European Institute of Innovation and Technology, EIT (body of the European Union that receives support from the European Union’s Horizon 2020 research and innovation programme), under the grant agreement CI22–00230. Likewise, this study was financially promoted by the “hna Foundation”. Dr. Vega is supported by the Spanish “Ministerio de Ciencia, Innovación y Universidades/FEDER” [RTI2018–102242-B-I00]. Dr. Rodriguez de Córdoba is supported by the Spanish “Ministerio de Economia y Competitividad/FEDER [SAF2015–66287-R]. Dr. Vega and Dr. Rodriguez de Córdoba are also funded by the Autonomous Region of Madrid [S2022/BMD-7278] and the European Commission – NextGenerationEU through CSIC’s Global Health Platform (”PTI Salud Global”) [SGL2103020]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

Protein-protein binding kinetics by biolayer interferometry, Running title: Binding kinetics by BLI

  • Santos-López, Jorge
  • Gómez, Sara
  • Fernández, Francisco J.
  • Vega, María Cristina
22 p.-3 fig., The specific kinetics and thermodynamics of protein-protein interactions underlie the molecular mechanisms of cellular functions; hence the characterization of these interaction parameters is central to the quantitative understanding of physiological and pathological processes. Many methods have been developed to study protein-protein interactions, which differ in various features including the interaction detection principle, the sensitivity, whether the method operates in vivo, in vitro, or in silico, the temperature control, the use of labels, immobilization, the amount of sample required, the number of measurements that can be accomplished simultaneously, or the cost. Bio-Layer Interferometry (BLI) is a label-free biophysical method to measure the kinetics of protein-protein interactions. Label-free interaction assays are a broad family of methods that do not require protein modifications (other than immobilization) or labels such as fusions with fluorescent proteins or transactivating domains or chemical modifications like biotinylation or reaction with radionuclides. Besides BLI, other label-free techniques that are widely used for determining protein-protein interactions include surface plasmon resonance (SPR), thermophoresis, and isothermal titration calorimetry (ITC), among others., This work was funded by the Spanish Ministerio de Ciencia, Innovación y Universidades-FEDER grants RTI2018-102242-BI00 (MCV), the Spanish Ministerio de Ciencia e Innovación-Recovery, Transformation and Resilience Plan (PRTR) grant PDC2022-133713-I00 (MCV), grant S2022/BMD-7278 of the Regional Government of Madrid (MCV), the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) (SGL2103020) (MCV), and the CSIC Special Intramural Grant PIE201620E064 (MCV). It was additionally supported by the Research Network on Complement in Health and Disease (RED2022-134750-T). KdlP was supported by an Industrial PhD grant (IND2018-010094) awarded by the Spanish Ministerio de Economía y Competitividad. JSL acknowledges the support of the PhD program in Molecular Biosciences of the Universidad Autónoma de Madrid (UAM) and the Ministry of Education, Culture and Sports of Spain (FPU Grant 17/06090). KdlP acknowledges the support of the PhD program in Biochemistry, Molecular Biology and Biomedicine of the Universidad Complutense de Madrid (UCM)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Otros (Other)

X-ray crystallography for macromolecular complexes, Running title: XRD for macromolecular complexes

  • Fernández, Francisco J.
  • Querol-García, Javier
  • Navas-Yuste, Sergio
  • Martino, Fabrizio
  • Vega, María Cristina
22 p.-4 fig., X-ray crystallography has for most of the last century been the standard technique to determine the high-resolution structure of biological macromolecules, including multi-subunit protein-protein and protein-nucleic acids as large as the ribosome and viruses. As such, the successful application of X-ray crystallography to many biological problems revolutionized biology and biomedicine by solving the structures of small molecules and vitamins, peptides and proteins, DNA and RNA molecules, and many complexes-affording a detailed knowledge of the structures that clarified biological and chemical mechanisms, conformational changes, interactions, catalysis and the biological processes underlying DNA replication, translation, and protein synthesis. Now reaching well into the first quarter of the twenty-first century, X-ray crystallography shares the structural biology stage with cryo-electron microscopy and other innovative structure determination methods, as relevant and central to our understanding of biological function and structure as ever. In this chapter, we provide an overview of modern X-ray crystallography and how it interfaces with other mainstream structural biology techniques, with an emphasis on macromolecular complexes., This work was supported by Spanish Ministerio de Ciencia, Innovación y Universidades-FEDER grant RTI2018-102242-B-I00 (MCV), the Spanish Ministerio de Ciencia e Innovación-Recovery, Transformation and Resilience Plan (PRTR) grant PDC2022-133713-I00 (MCV), grant S2022/BMD-7278 of the Regional Government of Madrid (MCV), the European Commission – NextGenerationEU through CSIC’s Global Health Platform (“PTI Salud Global”) (SGL2103020) (MCV), and the CSIC Special Intramural Grant PIE201620E064 (MCV). It was additionally supported by the Research Network on Complement in Health and Disease (RED2022-134750-T)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

C-model: A comprehensive enhanced pharmacokinetic/pharmacodynamic simulation environment targeting the complement system

  • Alfonso-González, Lucía
  • Vega, María Cristina
  • Fernández, Francisco J.
Recently, there has been increased research on treatments that modulate the complement system because of its significance in many diseases. However, managing patients with complement-related diseases is challenging owing to the different responses to treatments because of the heterogeneity of the aetiology of the different diseases, which may affect different proteins of the complement activation cascade. This study addresses these challenges using a comprehensive computational model, C-model., LAG acknowledges the support of the PhD program in Medicinal Chemistry of the Universidad Complutense de Madrid (UCM). This work was funded by Spanish Ministerio de Ciencia, Innovación y Universidades-FEDER grant RTI2018-102242-B-I00 (MCV); the Spanish Ministerio de Ciencia e Innovación-Recovery, Transformation and Resilience Plan (PRTR) grants PDC2022-133713-I00 (MCV) and CPP2022-009838 (FJF and MCV); grants S2017/BMD-3673 and S2022/BMD-7278 of the Regional Government of Madrid (MCV); the European Commission – NextGenerationEU through CSIC's Global Health Platform (‘PTI Salud Global’) (SGL2103020) (MCV); and the CSIC Special Intramural Grant PIE-201620E064 (MCV). It was additionally supported by the Research Network on Complement in Health and Disease (RED2022-134750-T) (MCV). We also acknowledge the CSIC Network of Rare Diseases (RER-CSIC). LAG was supported by an Industrial PhD grant (IND2019/BMD-17219) from the Regional Government of Madrid (FJF and MCV)., Peer reviewed